A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo

Acute myeloid leukemia (AML), the most frequent leukemia in adults, is driven by recurrent somatically acquired genetic lesions in a restricted number of genes. Treatment with tyrosine kinase inhibitors has demonstrated that targeting of prevalent FMS-related receptor tyrosine kinase 3 (FLT3) gain-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannakopoulou, Eirini, Lehander, Madeleine, Virding Culleton, Stina, Yang, Weiwen, Li, Yingqian, Karpanen, Terhi, Yoshizato, Tetsuichi, Rustad, Even H., Nielsen, Morten Milek, Bollineni, Ravi Chand, Tran, Trung T., Delic-Sarac, Marina, Gjerdingen, Thea Johanne, Douvlataniotis, Karolos, Laos, Maarja, Ali, Muhammad, Hillen, Amy, Mazzi, Stefania, Chin, Desmond Wai Loon, Mehta, Adi, Holm, Jeppe Sejerø, Bentzen, Amalie Kai, Bill, Marie, Griffioen, Marieke, Gedde-Dahl, Tobias, Lehmann, Sören, Jacobsen, Sten Eirik W., Woll, Petter S., Olweus, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597840/
https://www.ncbi.nlm.nih.gov/pubmed/37783807
http://dx.doi.org/10.1038/s43018-023-00642-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597840/
https://www.ncbi.nlm.nih.gov/pubmed/37783807
http://dx.doi.org/10.1038/s43018-023-00642-8

Ejemplares similares